SONN Company Profile and Key Details

Sonnet BioTherapeutics Holdings, Inc. generated EPS of -$8.22 over the past year. Five-year average earnings growth is 85.27%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $20.00. The high target offers 1487.3% upside. The low target suggests 1487.3% downside. The mean target is $20.00. This offers 1487.3% upside. Sonnet BioTherapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2025, missed forecasts by 93.88%. The prior quarter beat by -3.26%. Over the last six quarters, Apple has recorded several small beats. These include -8.44% in August 12, 2024.

SONN has shown weak momentum, losing -74.02% over the past week and -59.74% over the past quarter, though year-to-date performance is down -13.7%. Short-term trend indicators are mixed aligned (SMA20 -71.01%, SMA50 -72.7%, SMA200 -58.17%). The stock’s 14-day RSI is 28.16 (weak momentum), while the ATR of 0.88 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.47% below its high and over 16.67% above its low.

Sonnet BioTherapeutics Holdings, Inc. has 6.83 million shares outstanding. The public float is 6.72 million shares, elevated short interest at 27.88% of float. This equals 1.88 million shares. The short ratio is 1.51 days. Institutional investors hold 10.39% of the float. Insiders own 4.25%. Mohan Pankaj holds 59.53 thousand shares, Kenney Richard T has 50.00 thousand shares and SPITCAUFSKY LARRY has 40.00 thousand shares.

Sonnet BioTherapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.42. This means the shares are trading below this model’s fair value.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) closed at $1.26 USD, losing -$1.84 (-59.35%) from the previous close of $3.10. The stock is currently mid-range between its 52-week high and low $1.08 and $19.30. With a market capitalization of about $8.43 million, Sonnet BioTherapeutics Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 1.11 million shares, trading with heavier-than-usual volume. Headquartered in Princeton, NJ, Sonnet BioTherapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raghu Rao, the company employs approximately 13 people and listed since October 31, 2006. Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.

Sonnet BioTherapeutics Holdings, Inc. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 8.43 and a price-to-book ratio of 0.48 suggesting the stock is closer to book value. The P/FCF stands at -0.66, also above market averages.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are down -13.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sonnet BioTherapeutics Holdings, Inc. trading at a premium to the broader market with a P/E of -0.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.71, suggesting 988.1% upside. Our AI forecast model points to short-term strength (56.35% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-97.62% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Sonnet BioTherapeutics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 56.35%, with price expected at $1.97 by December 16, 2025, within a range of $1.28 to $2.71 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by March 02, 2026, with a range of $0.00 to $0.02. 1-Year Outlook: Projected loss of -97.62%, with price at $0.03 by December 02, 2026, within a range of $0.00 to $3.77.